EWTX
Edgewise Therapeutics, Inc.NASDAQHealthcare$33.33+0.57%ClosedMarket Cap: $3.58B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.47
P/S
0.00
EV/EBITDA
-19.31
DCF Value
$0.50
FCF Yield
-4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.0%
ROA
-30.4%
ROIC
-36.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-56.0M | $-50.2M | $-0.47 | — |
| FY 2025 | $0.00 | -Infinity% | $-191.4M | $-167.8M | $-1.63 | — |
| Q3 2025 | $0.00 | NaN% | $-46.9M | $-40.7M | $-0.39 | — |
| Q2 2025 | $0.00 | NaN% | $-42.6M | $-36.1M | $-0.34 | — |
| Q1 2025 | $0.00 | NaN% | $-46.0M | $-40.8M | $-0.43 | — |
| Q4 2024 | $0.00 | NaN% | $-45.5M | $-39.7M | $-0.42 | — |
| FY 2024 | $0.00 | NaN% | $-158.8M | $-133.8M | $-1.45 | — |
| Q3 2024 | $0.00 | NaN% | $-40.4M | $-34.1M | $-0.36 | — |
| Q2 2024 | $0.00 | NaN% | $-38.1M | $-31.5M | $-0.34 | — |
| Q1 2024 | $0.00 | NaN% | $-34.8M | $-28.5M | $-0.33 | — |
| Q4 2023 | $0.00 | NaN% | $-33.9M | $-30.1M | $-0.47 | — |
| FY 2023 | $0.00 | NaN% | $-114.4M | $-100.2M | $-1.57 | — |